Roivant Sciences officer proposes $7.32M share sale

The stated plan date is June 30, 2026, and the recent-sales table records transactions from August 20 through October 20.

Rhea-AI Filing Summary

Eric Venker, an officer of Roivant Sciences Ltd. (ROIV), reported a proposed sale of 200,000 common shares with an aggregate market value of $7,317,764.00. The shares are to be sold pursuant to a Rule 10b5-1 trading plan adopted on June 30, 2026. He also reported four sales during the preceding three months, dated August 20, August 28, September 30, and October 20, 2026.

Key Figures

Proposed shares: 200,000 common shares Aggregate market value: $7,317,764.00 Shares and reported amount: 13,909 shares; $512,407.56 +3 more

6 metrics

Proposed shares 200,000 common shares Proposed sale

Aggregate market value $7,317,764.00 Proposed sale

Shares and reported amount 13,909 shares; $512,407.56 Sale reported for August 20, 2026

Shares and reported amount 200,000 shares; $7,147,087.91 Sale reported for August 28, 2026

Shares and reported amount 200,000 shares; $7,323,556.00 Sale reported for September 30, 2026

Shares and reported amount 200,000 shares; $7,023,513.39 Sale reported for October 20, 2026

Key Terms

Rule 10b5-1 trading plan, Rule 144, RSU Grant

3 terms

Rule 10b5-1 trading plan regulatory

"sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

RSU Grant financial

"RSU Grant 018305 - Grant date 05/20/2020"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ROIV shares did Eric Venker propose to sell?

Eric Venker reported a proposed sale of 200,000 ROIV common shares with an aggregate market value of $7,317,764.00. The shares are to be sold pursuant to a Rule 10b5-1 trading plan adopted on June 30, 2026.

What sales did Eric Venker report for ROIV in the previous three months?

He reported 13,909 shares and a reported amount of $512,407.56 on August 20, 2026; 200,000 shares and $7,147,087.91 on August 28, 2026; 200,000 shares and $7,323,556.00 on September 30, 2026; and 200,000 shares and $7,023,513.39 on October 20, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/28/2026 - 04:36 PM EDT Accepted by SEC EDGAR 10/28/2026 - 04:35 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001801917
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Roivant Sciences Ltd.
SEC File Number	001-40782
Address of Issuer	7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM SW1H 0DB
Phone	441-295-5950
Name of Person for Whose Account the Securities are To Be Sold	Venker Eric
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Rockefeller Financial LLC 45 Rockefeller Plaza Floor 5 New York NY 10111	200000	7317764.00	722323015	10/28/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Shares	03/20/2025	Options Exercise - Grant Date 04/20/2022	Roivant Sciences Ltd.			14023	03/20/2025	n/a
Common Shares	02/20/2025	RSU Grant 018305 - Grant date 05/20/2020	Roivant Sciences Ltd.			8847	02/20/2025	n/a
Common Shares	01/20/2025	RSU Grant 018305 - Grant date 05/20/2020	Roivant Sciences Ltd			8847	01/20/2025	n/a
Common Shares	03/24/2025	RSU Grant 018305 - Grant date 05/20/2020	Roivant Sciences Ltd			11110	03/24/2025	n/a
Common Shares	03/20/2024	RSU Grant 018861 - Grant date 05/20/2021	Roivant Sciences Ltd			4087	03/20/2024	n/a
Common Shares	11/16/2023	RSU Grant 018861 - Grant date 05/20/2021	Roivant Sciences Ltd			3913	11/16/2023	n/a
Common Shares	10/18/2023	RSU Grant 018861 - Grant date 05/20/2021	Roivant Sciences Ltd			3372	10/18/2023	n/a
Common Shares	06/02/2025	Options Exercise - Grant Date 04/20/2022	Roivant Sciences Ltd			145801	06/02/2025	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway, London X0 SW1H0DB	Common Shares	08/20/2026	13909	512407.56
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H0DB	Common Shares	08/28/2026	200000	7147087.91
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H0DB	Common Shares	09/30/2026	200000	7323556.00
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H0DB	Common Shares	10/20/2026	200000	7023513.39

144: Remarks and Signature

Remarks	The shares reported on this Form 144 will be sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 06/30/2026.
Date of Notice	10/28/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/30/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Carmen Zamores as a duly authorized representative of National Financial Services LLC, as attorney-in-fact for Venker Eric
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)